
Ex-Premier Foods boss to advise KKR on Lucozade and Ribena bid
KKR is understood to have brought in Michael Clarke, the former CEO of Premier Foods, to advise on its £1.5bn bid for Lucozade and Ribena from GlaxoSmithKline (GSK).
According to Sky News, the appointment with KKR is his first UK role following his resignation from Premier Foods. If KKR is successful in its bid for GSK's drinks division, it could see Clarke taking up a seat on the board.
The appointment is likely to raise a few eyebrows in the City as Clarke's departure from the major UK food business came as a surprise, causing a 12% drop in the company's share price and many commentators pointing to the near-impossible asset disposal programme he was tackling as the trigger. Clarke left Warburg Pincus-backed Premier Foods at the start of this year after only 18 months in the job.
At the time of his exit, Clarke told reporters that he wanted to become CEO of a large corporation, and that now he had put Premier back on its feet it was time for someone else to take the lead. Indeed, while he was at the top, Premier Foods paid down its debt from £1.4bn to £973m, delivered four quarters of organic growth and an impressive £60m worth of cost savings ahead of plans. He expressed his interest in moving into a role where he would be focusing on growth rather than turnaround.
KKR declined to comment on the appointment.
GSK is believed to be disposing of its drinks division, which comprises well-known brands Lucozade and Ribena, to focus on its core consumer health operations. The pharmaceutical giant has brought in Greenhill and JP Morgan to advise on the deal.
According to reports, Blackstone and Lion Capital have teamed up to make a formal bid for the drinks division after they appointed Rothschild to advise.
Also believed to be in the running for the drinks brands are Permira, Bain Capital and CVC, as well as trade players Suntory and Nestlé.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater